These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 22197676)

  • 1. Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial.
    Pfirrmann M; Ehninger G; Thiede C; Bornhäuser M; Kramer M; Röllig C; Hasford J; Schaich M;
    Lancet Oncol; 2012 Feb; 13(2):207-14. PubMed ID: 22197676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: a GOELAMS study.
    Guièze R; Cornillet-Lefebvre P; Lioure B; Blanchet O; Pigneux A; Recher C; Bonmati C; Fegueux N; Bulabois CE; Bouscary D; Vey N; Delain M; Turlure P; Himberlin C; Harousseau JL; Dreyfus F; Béné MC; Ifrah N; Chevallier P;
    Am J Hematol; 2012 Dec; 87(12):1052-6. PubMed ID: 22911473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis.
    Versluis J; Hazenberg CL; Passweg JR; van Putten WL; Maertens J; Biemond BJ; Theobald M; Graux C; Kuball J; Schouten HC; Pabst T; Löwenberg B; Ossenkoppele G; Vellenga E; Cornelissen JJ;
    Lancet Haematol; 2015 Oct; 2(10):e427-36. PubMed ID: 26686044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re-analysis of the outcomes of post-remission therapy for acute myeloid leukemia with core binding factor according to years of patient enrollment.
    Shin HJ; Kim HJ; Sohn SK; Min YH; Won JH; Kim I; Yoon HJ; Lee JH; Jo DY; Joo YD; Jung CW; Lee KH; ; Chung JS; Ahn JS; Kim SJ; Lee JH; Choi SJ; Lee JH; Bae SH; Hong DS; Zang DY; Kim SH; Lee JL; Bang SM
    Jpn J Clin Oncol; 2010 Jun; 40(6):556-66. PubMed ID: 20185460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations.
    Xu Y; Sun Y; Shen H; Ding L; Yang Z; Qiu H; Sun A; Chen S; Wu D
    Am J Hematol; 2015 Nov; 90(11):992-7. PubMed ID: 26223865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group.
    Tsukimoto I; Tawa A; Horibe K; Tabuchi K; Kigasawa H; Tsuchida M; Yabe H; Nakayama H; Kudo K; Kobayashi R; Hamamoto K; Imaizumi M; Morimoto A; Tsuchiya S; Hanada R
    J Clin Oncol; 2009 Aug; 27(24):4007-13. PubMed ID: 19620491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.
    Brunet S; Labopin M; Esteve J; Cornelissen J; Socié G; Iori AP; Verdonck LF; Volin L; Gratwohl A; Sierra J; Mohty M; Rocha V
    J Clin Oncol; 2012 Mar; 30(7):735-41. PubMed ID: 22291086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups.
    Zittoun RA; Mandelli F; Willemze R; de Witte T; Labar B; Resegotti L; Leoni F; Damasio E; Visani G; Papa G
    N Engl J Med; 1995 Jan; 332(4):217-23. PubMed ID: 7808487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stratification of de novo adult acute myelogenous leukemia with adverse-risk karyotype: can we overcome the worse prognosis of adverse-risk group acute myelogenous leukemia with hematopoietic stem cell transplantation?
    Yoon JH; Kim HJ; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW
    Biol Blood Marrow Transplant; 2014 Jan; 20(1):80-8. PubMed ID: 24149098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial.
    Schaich M; Parmentier S; Kramer M; Illmer T; Stölzel F; Röllig C; Thiede C; Hänel M; Schäfer-Eckart K; Aulitzky W; Einsele H; Ho AD; Serve H; Berdel WE; Mayer J; Schmitz N; Krause SW; Neubauer A; Baldus CD; Schetelig J; Bornhäuser M; Ehninger G
    J Clin Oncol; 2013 Jun; 31(17):2094-102. PubMed ID: 23630210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.
    Krug U; Röllig C; Koschmieder A; Heinecke A; Sauerland MC; Schaich M; Thiede C; Kramer M; Braess J; Spiekermann K; Haferlach T; Haferlach C; Koschmieder S; Rohde C; Serve H; Wörmann B; Hiddemann W; Ehninger G; Berdel WE; Büchner T; Müller-Tidow C; ;
    Lancet; 2010 Dec; 376(9757):2000-8. PubMed ID: 21131036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial.
    Stelljes M; Middeke JM; Bug G; Wagner-Drouet EM; Müller LP; Schmid C; Krause SW; Bethge W; Jost E; Platzbecker U; Klein SA; Schubert J; Niederland J; Kaufmann M; Schäfer-Eckart K; Schaich M; Baldauf H; Stölzel F; Petzold C; Röllig C; Alakel N; Steffen B; Hauptrock B; Schliemann C; Sockel K; Lang F; Kriege O; Schaffrath J; Reicherts C; Berdel WE; Serve H; Ehninger G; Schmidt AH; Bornhäuser M; Mikesch JH; Schetelig J;
    Lancet Haematol; 2024 May; 11(5):e324-e335. PubMed ID: 38583455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia.
    Tsimberidou AM; Stavroyianni N; Viniou N; Papaioannou M; Tiniakou M; Marinakis T; Skandali A; Sakellari I; Yataganas X;
    Cancer; 2003 Apr; 97(7):1721-31. PubMed ID: 12655529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of allogeneic haematopoietic stem cell transplantation in patients with abnl(17p) acute myeloid leukaemia.
    Mohr B; Schetelig J; Schäfer-Eckart K; Schmitz N; Hänel M; Rösler W; Frickhofen N; Link H; Neubauer A; Schuler U; Platzbecker U; Middeke JM; Ehninger G; Bornhäuser M; Schaich M; Stölzel F;
    Br J Haematol; 2013 Apr; 161(2):237-44. PubMed ID: 23432431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical outcome of FLT3-ITD (+) acute myeloid leukemia patients treated with allogeneic hematopoietic stem cell transplantation].
    Yang Z; Tian H; Xu Y; Qiu H; Chen S; Sun A; Wu D
    Zhonghua Nei Ke Za Zhi; 2014 Feb; 53(2):94-8. PubMed ID: 24767158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multivariate analyses of prognostic factors in acute myeloid leukemia: relevance of cytogenetic abnormalities and CD34 expression.
    Junghanss C; Waak M; Knopp A; Kleine HD; Kundt G; Leithäuser M; Hilgendorf I; Wolff D; Casper J; Freund M
    Neoplasma; 2005; 52(5):402-10. PubMed ID: 16151585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A.
    Schlenk RF; Döhner K; Mack S; Stoppel M; Király F; Götze K; Hartmann F; Horst HA; Koller E; Petzer A; Grimminger W; Kobbe G; Glasmacher A; Salwender H; Kirchen H; Haase D; Kremers S; Matzdorff A; Benner A; Döhner H
    J Clin Oncol; 2010 Oct; 28(30):4642-8. PubMed ID: 20805454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with internal tandem duplication of FLT3.
    Lin PH; Lin CC; Yang HI; Li LY; Bai LY; Chiu CF; Liao YM; Lin CY; Hsieh CY; Lin CY; Ho CM; Yang SF; Peng CT; Tsai FJ; Yeh SP
    Leuk Res; 2013 Mar; 37(3):287-92. PubMed ID: 23276395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
    Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
    J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.